Eli Lilly stock dips on Novo Nordisk's rival drug data By Investing.com

Published on 24 Jan 2025 on Investing.com

On Friday, Novo Nordisk released promising trial results for its obesity treatment, amycretin, which...

Read the rest of the article

Start tracking your investments with Statfolio

After analyzing data going back to 2016, one analyst thinks he has identified a seasonal pattern ...

The Wall Street Journal · via Yahoo Finance 29 Jan 2025

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are...

Insider Monkey · via Yahoo Finance 25 Jan 2025

On Friday, Novo Nordisk A/S NVO released topline results from a phase 1b/2a trial with amycretin ...

Benzinga 24 Jan 2025

Friday morning. What Novo Nordisk announced Novo Nordisk describes its latest work as "a phase 1b...

Motley Fool · via Yahoo Finance 24 Jan 2025

On Friday, Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with...

Benzinga · via AOL 24 Jan 2025

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest...

Yahoo Finance · via AOL 24 Jan 2025

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able t...

Market Watch 24 Jan 2025

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth...

Zacks · via Yahoo Finance 24 Jan 2025

We recently published a list of 10 Best Falling Stocks to Invest in Right Now. In this article, w...

Insider Monkey · via Yahoo Finance 24 Jan 2025

On Friday, Novo Nordisk released promising trial results for its obesity treatment, amycretin, wh...

Investing.com 24 Jan 2025